Developing a dynamic pharmacophore model for HIV-1 integrase

Journal of Medicinal Chemistry

Volumn 43, Issue 11, 2000, Pages 2100-2114

  Carlson, Heather A ^a   Masukawa, Kevin M ^a   Rubins, Kathleen ^b   Bushman, Fredric D ^b   Jorgensen, William L ^c   Lins, Roberto D ^d   Briggs, James M ^d   McCammon, J Andrew ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^c YALE UNIVERSITY   (United States)

^d University of Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE; INTEGRASE INHIBITOR;

ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHARMACOPHORE;

COMPUTER SIMULATION; DRUG EVALUATION, PRECLINICAL; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; MODELS, CHEMICAL; MODELS, MOLECULAR; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034212669     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990322h     Document Type: Article

References (84)

1. Coffin, J. M.; Hughes, S. H.; Varmus, H. E. Retroviruses; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 1997.
2. Hansen, M. S. T.; Carteau, S.; Hoffman, C.; Li, L.; Bushman, F. D. Retroviral cDNA integration: Mechanism, applications, and inhibition. In Genetic Engineering. Principles and Methods, Vol. 20; Setlow, J. K., Ed.; Plenum Press: New York, 1998; pp 41-63.
3. Asante-Appiah, E.; Skalka, A. M. Molecular mechanisms in retrovirus DNA integration. Antiviral Res. 1997, 36, 139-156.
4. Miller, M. D.; Farnet, C. M.; Bushman, F. D. Human immunodeficiency virus type 1 preintegration complexes: Studies of organization and composition. J. Virol. 1997, 71, 5382-5390.
5. Heuer, T. S.; Brown, P. O. Photo-cross-linking studies suggest a model for the architecture of an active human immunodeficiency virus type 1 integrase-DNA complex. Biochemistry 1998, 37, 6667-6678.
6. Zheng, R.; Jenkins, T. M.; Craigie, R. Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 13659-13664.
7. Esposito, D.; Craigie, R. Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interactions. EMBO J. 1998, 17, 5832-5843.
8. Jenkins, T. M.; Esposito, D.; Engelman, A.; Craigie, R. Critical contacts between HIV-1 integrase and viral DNA identified by structure-based analysis and photo-crosslinking. EMBO J. 1997, 16, 6849-6859.
9. Heuer, T. S.; Brown, P. O. Mapping features of HIV-1 integrase near selected sites on viral and target DNA molecules in an active enzyme-DNA complex by photo-cross-linking. Biochemistry 1997, 36, 10655-10665.
10. Eijkelenboom, A. P. A. M.; Puras Lutzhe, R. A.; Boelens, R.; Plasterk, R. H. A.; Kaptein, R.; Hård, K. The DNA-binding domain of HIV-1 integrase has and SH3-like fold. Nat. Struct. Biol. 1995, 2, 807-810.
11. Cai, M.; Zheng, R.; Caffrey, M.; Craigie, R.; Clore, G. M.; Gronenborn, A. M. Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nat. Struct. Biol. 1997, 4, 567-577.
12. Eijkelenboom, A. P. A. M.; van den Ent, F. M. I.; Vos, A.; Doreleijers, J. F.; Hård, K.; Tullius, T. D.; Plasterk, R. H. A.; Kaptein, R.; Boelens, R. The solution structure of the amino-terminal HHCC domain of HIV-2 integrase: A three-helix bundle stabilized by zinc. Curr. Biol. 1997, 7, 739-746.
13. Maignan, S.; Guilloteau, J.-P.; Zhou-liu, Q.; Clément-Mella, C.; Mikol, V. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: High level of similarity of the active site with other viral integrases. J. Mol. Biol. 1998, 282, 359-368.
14. Goldgur, Y.; Dyda, F.; Hickman, A. B.; Jenkins, T. M., Craigie, R.; Davies, D. R. Three new structures of the core domain of HIV-1 integrase: An active site that binds magnesium. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 9150-9154.
15. Dyda, F.; Hickman, A. B.; Jenkins, T. M.; Engelman, A.; Craigie, R.; Davies, D. R. Crystal structure of the catalytic domain of HIV-1 integrase: Similarity to other polynucleotidyl transferases. Science 1994, 266, 1981-1986.
16. Lins, R. D.; Briggs, J. M.; Straatsma, T. P.; Carlson, H. A.; Greenwald, J.; Choe, S.; McCammon, J. A. Molecular dynamics studies on the HIV-1 integrase catalytic domain. Biophys. J. 1999, 76, 2999-3011.
17. Bohm, H.-J.; Klebe, G. What can we learn from molecular recognition in protein-ligand complexes for the design of new drugs? Angew. Chem., Int. Ed. Engl. 1996, 35, 2588-2614.
18. Walters, W. P.; Stahl, M. T.; Murcko, M. A. Virtual screening-an overview. DDT 1998, 3, 160-178.
19. Allen, M. P.; Tildesley, D. J. Computer Simulation of Liquids; Oxford University Press: Oxford, U.K., 1994; pp 110-126.
20. Goldgur, Y.; Craigie, R.; Cohen, G. H.; Fujiwara, T.; Yoshinaga, T.; Fujishita, T.; Sugimoto, H.; Endo, T.; Murai, H.; Davies, D. R. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 13040-13043.
21. Bujacz, G.; Jaskólski, M.; Alexandratos, J.; Wlodawer, A.; Merkel, G.; Katz, R. A.; Skalka, A. M. High-resolution structure of the catalytic domain of avian sarcoma virus integrase. J. Mol. Biol. 1995, 253, 333-346.
22. MidasPlus; Computer Graphics Lab, University of California, San Diego.
23. Ferrin, T. E.; Huang, C. C.; Jarvis, L. E.; Langridge, R. The MIDAS display system. J. Mol. Graphics 1988, 6, 13-27.
24. Carlson, H. A.; Masukawa, K. M.; McCammon, J. A. Method for including the dynamic fluctuations of a protein in computer-aided drug design. J. Phys. Chem. A 1999, 103, 10213-10219.
25. Kuntz, I. D. Structure-based strategies for drug design and discovery. Science 1992, 257, 1078-1082.
26. Kuntz, I. D.; Meng, C. E.; Shoichet, B. K. Structure-based molecular design. Acc. Chem. Res. 1994, 27, 117-123.
27. Colman, P. M. Structure-based drug design. Curr. Opin. Struct. Biol. 1994, 4, 868-874.
28. Blundell, T. L. Structure-based drug design. Nature 1996, S384, 23-26.
29. Zheng, Q.; Kyle, D. J. Computational screening of combinatorial libraries via multicopy sampling. DDT 1997, 6, 229-234.
30. Marrone, T. J.; Briggs, J. M.; McCammon, J. A. Structure-based drug design: Computational advances. Annu. Rev. Pharmacol. Toxicol. 1997, 37, 71-90.
31. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 1985, 28, 849-857.
32. Goodsell, D. S.; Olson, A. J. Automated docking of substrates to proteins by simulated annealing. Proteins 1990, 8, 195-202.
33. Miranker, A.; Karplus, M. Functionality maps of binding sites: a multiple copy simultaneous search method. Proteins 1991, 11, 29-34.
34. Böhm, H.-J. The computer program LUDI: A new method for the de novo design of enzyme inhibitors. J. Comput.-Aided Mol. Des. 1992, 6, 61-78.
35. Caflisch, A.; Miranker, A.; Karplus, M. Multiple copy simultaneous search and construction of ligands in binding sites: Application to inhibitors of HIV-1 Aspartic Proteinase. J. Med. Chem. 1993, 36, 2142-2167.
36. Miranker, A.; Karplus, M. An automated method for dynamic ligand design. Proteins 1995, 23, 472-490.
37. Clark, D. E.; Frenkel, D.; Levy, S. A.; Li, J.; Murray, C. W.; Robson, B.; Waszkowycz, B.; Westhead, D. R. PRO_LIGAND: An approach to de novo molecular design. 1. Application to the design of organic molecules. J. Comput.-Aided Mol. Des. 1995, 9, 13-32.
38. Pearlman, D. A.; Murko, M. A. CONCERTS: Dynamic connection of fragments as an approach to de novo ligand design. J. Med. Chem. 1996, 39, 1651-1663.
39. Joseph-McCarthy, D.; Fedorov, A. A.; Almo, S. C. Comparison of experimental and computational functional group mapping of an RNase A structure: Implications for computer-aided drug design. Protein Eng. 1996, 9, 773-780.
40. Joseph-McCarthy, D.; Hogle, J. M.; Karplus, M. Use of the multiple copy simultaneous search (MCSS) method to design a new class of picornavirus capsid binding drugs. Proteins 1997, 29, 32-58.
41. Burt, S.; Hutchins, C.; Zielinski, P. J. A Monte Carlo method for finding important ligand fragments from receptor data. J. Comput.-Aided Mol. Des. 1997, 11, 243-255.
42. Castro, A.; Richards, W. G.; Lyne, P. D. The design of novel acetylcholinesterase inhibitors using the multiple copy simultaneous search method. Med. Chem. Res. 1999, 9, 98-107.
43. Jorgensen, W. L. BOSS Version 3.8; Yale University: New Haven, CT, 1997.
44. Probes in the first MUSIC simulations were used to identify catalytic sites around transition structures from ab initio molecular orbital calculations. Carlson H. A. Chapter 5: Design of catalytic hosts to promote the rearrangement of chorismate to prephenate. In Methodological Development and Bioorganic Applications of Computational Simulations. Thesis, Yale University, New Haven, CT, 1997.
45. Kaminski, G.; Jorgensen, W. L. Performance of the AMBER94, MMFF94, and OPLS-AA force fields for modeling organic liquids. J. Phys. Chem. 1996, 100, 18010-18013.
46. Beachy, M. D.; Chasman, D.; Murphy, R. B.; Halgren, T. A.; Friesner, R. A. Accurate ab initio quantum chemical determination of the relative energetics of peptide conformations and assessment of empirical force fields. J. Am. Chem. Soc. 1997, 119, 5908-5920.
47. Kaminski, G.; Duffy, E. M.; Matsui, T.; Jorgensen, W. L. Free-energies of hydration and pure liquid properties of hydrocarbons from the OPLS all-atom model. J. Phys. Chem. 1994, 98, 13077-13082.
48. Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 1996, 118, 11225-11236.
49. Zheng, Q.; Kyle, D. J. Multiple copy sampling: Rigid versus flexible protein. Proteins 1994, 19, 324-329.
50. Totrov, M.; Abagyan, R. Flexible protein-ligand docking by global energy optimization in internal coordinates. Proteins 1997, Suppl. 1, 215-220.
51. Ringe, D. What makes a binding site a binding site? Curr. Opin. Struct. Biol. 1995, 5, 825-829.
52. Hong, H.; Neamati, N.; Wang, S.; Nicklaus, M. C.; Mazumder, A.; Zhao, H.; Burke, T. R., Jr.; Pommier, Y.; Milne, G. W. A.: Discovery of HIV-1 integrase inhibitors by pharmacophore searching. J. Med. Chem. 1997, 40, 930-936.
53. Catalyst; Molecular Simulations Inc.: San Diego, CA, 1996.
54. Nicklaus, M. C.; Neamati, N.; Hong, H.; Mazumder, A.; Sunder, S.; Chen, J.; Milne, G. W. A.; Pommier, Y. HIV-1 integrase pharmacophore: Discovery of inhibitors through three-dimensional database searching. J. Med. Chem. 1997, 40, 920-929.
55. Neamati, N.; Hong, H.; Mazumder, A.; Wang, S.; Sunder, S.; Nicklaus, M. C.; Milne, G. W. A.; Proska, B.; Pommier, Y. HIV-1 integrase pharmacophore: Discovery of inhibitors through three-dimensional database searching. J. Med. Chem. 1997, 40, 942-951.
56. Neamati, N.; Hong, H.; Sunder, S.; Milne, G. W. A.; Pommier, Y. Potent inhibitors of human immunodeficiency virus type 1 integrase: Identification of a novel four-point pharmacophore and tetracyclines as novel inhibitors. Mol. Pharmacol. 1997, 52, 1041-1055.
57. Hong, H.; Neamati, N.; Winslow, H. E.; Christensen, J. L.; Orr, A.; Pommier, Y.; Milne, G. W. A.: Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore. Antiviral Chem. Chemother. 1998, 9, 461-472.
58. Neamati, N.; Sunder, S.; Pommier, Y. Design and discovery of HIV-1 integrase inhibitors. DDT 1997, 2, 487-498.
59. Farnet, C. M.; Wang, B.; Lipford, J. R.; Bushman, F. D. Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 9742-9747.
60. Farnet, C. M.; Wang, B.; Hansen, M.; Lipford, J. R.; Zalkow, L.; Robinson, W. E., Jr.; Siegel, J.; Bushman, F. D. Human immunodeficiency virus type 1 cDNA integration: New aromatic hydroxylated inhibitors and studies of the inhibition mechanism. Antimicrob. Agents Chemother. 1998, 42, 2245-2253.
61. Lubkowski, J.; Yang, F.; Alexandratos, J.; Wlodawer, A.; Zhao, H.; Burke, T. R., Jr.; Neamati, N.; Pommier, Y.; Merkel, G.; Skalka, A. M. Structure of the catalytic domain of avian sarcoma virus integrase with a bound HIV-1 integrase-targeted inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 4831-4836.
62. Artico, M.; Di Santo, R.; Costi, R.; Novellino, E.; Greco, G.; Massa, S.; Tramontano, E.; Marongiu, M. E.; De Montis, A.; La Colla, P. Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of HIV-1 integrase: Synthesis, biological evaluation, and molecular modeling. J. Med. Chem. 1998, 41, 3948-3960.
63. Zhu, K.; Cordeiro, M. L.; Atienza, J.; Robinson, W. E., Jr.; Chow, S. A. Irreversible inhibition of human immunodeficiency virus type 1 integrase by dicaffeoylquinic acids. J. Virol. 1999, 73, 3309-3316.
64. King, P. J.; Robinson, W. E., Jr. Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase. J. Virol. 1998, 72, 8420-8424.
65. Mazumder, A.; Neamati, N.; Sunder, S.; Schultz, J.; Pertz, H.; Eich, E.; Pommier, Y. Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action. J. Med. Chem. 1997, 40, 3057-3063.
66. Mekouar, K.; Mouscadet, J.-F.; Desmaële, D.; Subra, F.; Leh, H.; Savouré, D.; Auclair, C.; d'Angelo, J. Styrylquinoline derivatives: A new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells. J. Med. Chem. 1998, 41, 2846-2857.
67. Lin, Z.; Neamati, N.; Zhao, H.; Kiryu, Y.; Turpin, J. A.; Aberham, C.; Strebel, K.; Kohn, K.; Witvrouw, M.; Pannecouque, C.; Debyser, Z.; De Clercq, E.; Rice, W. G.; Pommier, Y.; Burke, T. R., Jr. Chicoric acid analogues as HIV-1 integrase inhibitors. J. Med. Chem. 1999, 42, 1401-1414.
68. Asante-Appiah, E.; Skalka, A. M. A metal-induced conformational change and activation of HIV-1 integrase. J. Biol. Chem. 1997, 272, 16196-16205.
69. Asante-Appiah, E.; Seeholzer, S. H.; Skalka, A. M. Structural determinants of metal-induced conformational changes in HIV-1 integrase. J. Biol. Chem. 1998, 273, 35078-35087.
70. Mazumder, A.; Gazit, A.; Levitzhi, A.; Nicklaus, M.; Yung, J.; Kohlhagen, G.; Pommier, Y. Effects of tyrophostins, protein kinase inhibitors, on human immunodeficiency virus type 1 integrase. Biochemistry 1995, 34, 15111-15122.
71. Mazumder, A.; Raghavan, K.; Weinstein, J.; Kohn, K. W.; Pommier, Y. Inhibition of human immunodeficiency virus type-1 integrase by curcumin. Biochem. Pharmacol. 1995, 49, 1165-1170.
72. Sánchez-Cortés, S.; Miskovsky, P.; Jancura, D.; Bertoluzza, A. Specific interactions of antiretroviraly active drug hypericin with DNA as studied by surface-enhanced resonance Raman spectroscopy. J. Phys. Chem. 1996, 100, 1938-1944.
73. Mazumder, A.; Wang, S.; Neamati, N.; Nicklaus, M.; Sunder, S.; Chen, J.; Milne, G. W. A.; Rice, W. G.; Burke, T. R., Jr.; Pommier, Y. Antiretroviral agents as inhibitors of both human immunodeficiency virus type-1 integrase and protease. J. Med. Chem. 1996, 39, 2472-2481.
74. Zhao, H.; Neamati, N.; Sunder, S.; Hong, H.; Wang, S.; Milne, G. W. A.; Pommier, Y.; Burke, T. R., Jr. Hydrazide-containing inhibitors of HIV-1. J. Med. Chem. 1997, 40, 937-941.
75. Craigie, R.; Mizuuchi, K.; Bushman, F. D.; Engelman, A. A rapid in vitro assay for HIV DNA integration. Nucleic Acids Res. 1991, 19, 2729-2734.
76. 50's for compound 3 are much lower: 57 and 37 μM for 3′-preprocessing and strand transfer, respectively.
77. InsightII; Molecular Simulations Inc.: San Diego, CA, 1997.
78. HBUILD; Polar hydrogen parameter set for CHARMm Version 22; Molecular Simulations Inc.: Waltham, MA, 1992.
79. Anchell, J.; Apra, E.; Bernholdt, D.; Borowski, P.; Clark, T.; Clerc, D.; Dachsel, H.; Deegan, M.; Dupuis, M.; Dyall, K. H.; Fruchtl, G. F.; Gutowski, M.; Harrison, R.; Hess, A.; Jaffe, J.; Kendall, R.; Kobayashi, R.; Kutteh, R.; Lin, Z.; Littlefield, R.; Long, X.; Meng, B.; Nichols, J.; Nieplocha, J.; Rendall, A.; Stave, M.; Straatsma, T. P.; Taylor, H.; Thomas, G.; Wolinski, K.; Wong, A. NWChem, A computational chemistry package for parallel computers, Version 3.2; High Performance Computational Chemistry Group, Pacific Northwest Laboratory: Richland, WA, 1998.
80. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M., Jr.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
81. Berendsen, H. J. C.; Grigerra, J. R.; Straatsma, T. P. The missing term in effective pair potentials. J. Phys. Chem. 1987, 91, 6269-6271.
82. Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T.; Lee, H.; Pedersen, L. G. A smooth particle mesh ewald method. J. Chem. Phys. 1995, 103, 8577-8593.
83. Briggs, J. M. Unpublished data.
84. Jorgensen, W. L.; Impey, R. W.; Chandrasekhar, J.; Madura, J. D.; Klein, M. L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 1983, 79, 926-935.